

www.lungtransplantation.org



16th International Congress on

LUNG TRANSPLANTATION

Paris, september 12-13, 2024

*Union Internationale
des Chemins de Fer
16 rue Jean Rey
Paris 15^e*

Endorsed by




Société
Francophone de
Transplantation



ESOT
Leading the way
in transplantation



Program



Dear Colleagues,

We are pleased to welcome you to the 16th International Congress on Lung Transplantation, which will be held in Paris on September 12-13 2024.

The scientific program will include new subjects in addition to classic topics, presented by eminent leaders in the field of transplantation.

Our hope is that numerous lectures and debates will be fruitful and have a positive impact on the future of each participant.

We look forward to welcoming you in the beautiful city of Paris.

Best regards,

*Antoine ROUX, Edouard SAGE
for the Organizing Committee*

Committees

* Local Organizing Committee

Honorary Presidents

Alain Bisson, Marc Stern

Presidents

Antoine Roux, Edouard Sage

Members

Olivier Brugière,
Alain Chapelier,
Dominique Grenet,
Abdul Hamid,
Morgan Le Guen,
Sandra de Miranda,
François Parquin,
Clément Picard,
Benjamin Zuber


* Presidents of the Congress

Pr Tereza Martinu (Toronto, Canada)

Pr Sandra Lindstedt (Lund, Sweden)

* International Scientific Committee

A. d'Armini (I)
P. Corris (UK)
R.D. Davis (USA)
T. Egan (USA)
M. Hertz (USA)
S. Keshavjee (CND)
W. Klepetko (A)
J.F. Mornex (F)
H. Reichenspurner (D)
G. Snell (AUS)
A. Varela (SP)



Scientific Information

* If you are a chairperson

You must be in your session room 10 minutes prior the beginning of the session.

Make sure that all speakers observe timing.

Participants should not speak without permission.

They should first clearly state their name, institution and country.

* Congress Dinner *Upon reservation*

The Congress Dinner will take place at the restaurant "RADIOEAT" on thursday, 8.30 pm.

RADIOEAT

116 Av. du Président Kennedy - 75016 Paris

Price per person: 75 Euros

RER station: Line C, Avenue du Président Kennedy / Maison de Radio France

* Technical Exhibition

The technical exhibit is located close to the conference rooms. Please plan to visit the exhibit regularly, and especially during the breaks.

| | | |
|-------------|-----------|--------------|
| Exhibitors: | SANOFI | THERMOFISHER |
| | TAKEDA | XVIVO |
| | THERADIAL | |

* Administrative Secretariat

Office hours during the congress:

• **Thursday 12:**
7:30 - 18:30

• **Friday 13:**
7:30 - 16:30

After the congress:

VBC - Lung Transplantation

223 avenue Emile Counord

33300 Bordeaux (France)

Phone: +33 (0)1 45 33 60 46

e-mail: c.deplagne@vbce.fr

Website: www.vbce.fr

* If you are a speaker

Locate your session room in due time.

Speakers must go to the preview room and turn in their slides or computer-assisted presentations that will be handed out to the session room.

Personal laptops cannot be used for the presentations.

In the session room, strictly follow instructions from the chairperson, in particular those regarding the timing of your presentation.

General Information

* Badges

For security and regulation reasons, all participants will be required to wear their badge at all times throughout the Congress.

* Certificate of attendance

A certificate of attendance for registered participants will be available after the congress, from September 16, on the congress website.

* Insurance

The Organizers do not accept responsibility for individual medical, travel or personal insurance. Delegates are strongly advised to take out their own personal insurance policy.

Secretariats

* Scientific Secretariat

Pr Antoine ROUX et Pr Edouard SAGE

Hôpital Foch - Service de Pneumologie

40 rue Worth - 92151 Suresnes (France)



Phone: +33 (0)1 46 25 22 44


e-mails: a.roux@hopital-foch.com

e.sage@hopital-foch.com

Program Overview



| Thursday 12 | Room Louis Armand | Room Friedrich List |
|---------------|---|--|
| 8:45 → 9:00 | Welcome | |
| 9:00 → 9:45 | Big Picture 1 - The role of innate allorecognition in transplantation - Breaking the dogma | |
| 9:45 → 10:00 | | Break |
| 10:00 → 11:40 | Donor to recipient: The new age of selection and matching | Infectious diseases |
| 11:40 → 12:25 | Big Picture 2 - Ex vivo lung perfusion: from preservation to organ regeneration | |
| 12:30 → 13:30 | Lunch Symposium  Therakos ECP in lung transplantation: from treating to preventing - What? How? What for? | |
| 13:50 → 15:50 | Donor management and graft preservation | Session supported by sanofi Graft dysfunction: basics of physiopathology |
| 15:50 → 16:15 | | Break |
| 16:15 → 18:15 | Reviving respiration: innovations in organ preservation and ex vivo lung perfusion | Graft dysfunction: biomarkers |
| Friday 13 | Room Louis Armand | Room Friedrich List |
| 9:00 → 10:30 | PGD precision: navigating perioperative strategies for optimal outcomes | Evil humors: antibodies and how to tame them (Post LTx) |
| 10:30 → 10:45 | | Break |
| 10:45 → 12:15 | Pre-transplant allosensitization and induction strategies | Clinical aspects of allograft dysfunction: diagnostics to therapeutics |
| 12:15 → 12:45 | | Break |
| 12:45 → 13:45 | CMV - Academic symposium supported by GRIFOLS  | |
| 13:45 → 14:00 | | Break |
| 14:00 → 14:45 | Poster session - Poster Exhibit | |
| 14:45 → 16:45 | Next Future | |
| 16:45 → 17:00 | Closing discussion | |



Thursday 12

Scientific Program

8:45 → 9:00

Room Louis Armand

Welcome

Introduction

Presidents of the Congress:

Tereza Martinu (Toronto, Canada),

Sandra Lindstedt (Lund, Sweden)

Presidents of the Local Organizing Committee:

Antoine Roux, Edouard Sage

(Suresnes, France)

9:00 → 9:45

Room Louis Armand

Big Picture 1

Chairs: **Daniel Calabrese** (San Francisco, USA)

Laurie Snyder (Durham, USA)

The role of innate allorecognition in transplantation - Breaking the dogma

Fadi Lakkis (Pittsburgh, USA)

35 min + 10 min Q&A

9:45 → 10:00

Break

10:00 → 11:40

Room Louis Armand

Donor to recipient: The new age of selection and matching

Chairs: **Olaf Mercier** (Le Plessis Robinson, France)

Anne Olland (Strasbourg, France)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

10:00 From LAS to CAS : the moving targets of lung allocation in the USA
Carli Lehr (Cleveland, USA)

10:15 Extending the boundaries of life : advancements in age-inclusive donor criteria for lung transplantation
Laurens Ceulemans (Leuven, Belgium)

10:30 01 - Effect of donor age on survival in lung transplantation: retrospective study from a multicentric cohort
Philippe Lacoste (Nantes, France)


10:37 02 - Donor to recipient age matching in lung transplantation: a European experience
Pauline Pradere (Paris, France)

10:44 Donor and recipient frailty assessment and its prognostic utility
Lianne Singer (Toronto, Canada)

10:59 Can we modify frailty: pre-transplant rehabilitation strategies
Irene Bello (Barcelona, Spain)

11:14 Recipients with pulmonary hypertension: donor selection and management
Laurent Savale (Paris, France)

11:29 03 - Outcomes of listing for lung and heart-lung transplantation in pulmonary hypertension: comparative experience in France and the United Kingdom
Pauline Pradere (Paris, France)



10:00 → 11:40

Room Friedrich List

Infectious diseases

Chairs: Fanny Lanternier (Paris, France)
Shahid Husain (Toronto, Canada)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

10:00 Good food, good mood: let's eat right after lung transplantation
Anastasia Saade (Rennes, France)

10:15 Infection prophylaxis in lung transplant recipients: How best to prevent fungal infections"
Shahid Husain (Toronto, Canada)

10:30 **04** - Battling *Aspergillus* after lung transplantation: risk factors, statins, and the impact on chronic lung allograft dysfunction
Anna Van Gemert (Groningen, The Netherlands)

10:37 **05** - Ready for prime time?
A systematic review of cytomegalovirus immune monitoring assays for predicting CMV-related events in lung transplant
Cesar Berto (Boston, USA) *Vidéo*

10:44 New antibiotics on the block
Benoît Pilmis (Paris, France)

10:59 **06** - Rapid molecular detection of multidrug resistant bacteria in donor lungs as a strategy to optimize peri-operative prophylactic antibiotics
Rayid Abdulqawi (Riyadh, Saudi Arabia)

11:06 Phage therapy in lung transplantation
Christian Kuehn (Hannover, Germany)

11:21 Lessons learned from COVID-19 and what future pandemics await us?
Robin Avery (Baltimore, USA) *Visio*

11:40 → 12:25

Room Louis Armand

Big Picture 2

Chairs: Sandra Lindstedt (Lund, Sweden)
Edouard Sage (Suresnes, France)

Ex vivo lung perfusion: from preservation to organ regeneration

Marcelo Cypel (Toronto, Canada)

35 min + 10 min Q&A

12:30 → 13:30


Room Louis Armand

Lunch Symposium Therakos

ECP in lung transplantation: from treating to preventing - What? How? What for?

Chair: Jonathan Messika (Suresnes, France)

- Introduction
Jonathan Messika (Suresnes, France)
- Randomized controlled trial on the use of ECP as a preventional approach after lung transplantation
Peter Jaksch (Vienna, Austria)
- Pre-clinical data on the use of ECP to prevent late complications after LTx
James Hutchinson (Regensburg, Germany)
- Discussion - Use of ECP in lung transplant recipients - From treatment to prevention
All - Q&A



Thursday 12

Scientific Program

13:50 → 15:50

Room Louis Armand

Donor management and graft preservation

Chairs: **Alberto Benazzo** (Vienna, Austria)
Shaf Keshavjee (Toronto, Canada)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

13:50 Not too cold and not too hot, just right? Varying degrees of lung preservation (1.5 min + 3 min Q&A)
Marcelo Cypel (Toronto, Canada)

14:08 **07** - Metabolomic studies reveal an organ-protective hibernation state during donor lung preservation at 10°C
Aizhou Wang (Toronto, Canada)

14:15 **08** - Lung transplant outcomes after implementation of a hospital-based 10°C refrigeration for cold organ preservation
Alexey Abramov (New York, USA)

14:22 **09** - The impact of donor ventilation duration on pulmonary function post-lung transplantation
Alim Hirji (Alberta, Canada)

14:29 **010** - Analysing the utility of single lung transplantation in interstitial lung disease using discrete event simulation of donor organ allocation
Samuel Kennedy (Newcastle, UK)


14:36 **011** - Results of uncontrolled donation after cardio-circulatory death program (12 min + 3 min Q&A)
Alessandro Palleschi (Milan, Italy)

14:51 **012** - Effect of time from Brain Stem Death (BSD) on post lung transplant outcome: prolonging time to retrieval could be of benefit (12 min + 3 min Q&A)
John Dark (Newcastle, UK)

15:06 **013** - The impact of thoraco-abdominal normothermic regional perfusion on lung grafts evaluated by ex-vivo lung perfusion
Matthieu Glorion (Suresnes, France)

15:13 **014** - UK experience of direct procurement of lungs with ongoing abdominal normothermic regional perfusion from controlled DCD donors
Luke Williams (Cambridge, UK)

15:20 Debate: Normothermic Regional Perfusion (NRP) in lung transplant: what do we do with it and do we need EVLP?
• Pro: **Marius Berman** (Papworth, UK) (10 min)
• Con: **Arne Neyrinck** (Leuven, Belgium) (10 min)
• Q&A / Rebuttle (7 min)



13:50 → 15:50

Room Friedrich List

Session supported by **sanofi**

Graft dysfunction: basics of physiopathology

Chairs: **Stephen Juvet** (Toronto, Canada)
Adrien Tissot (Nantes, France)

Invited speaker

Selected Abstract: 5 min + 2 min Q&A

13:50 Clinical and pathophysiologic parallels between CLAD and chronic pulmonary GVHD: Clinical analysis (12 min)
Anne Bergeron (Geneva, Switzerland)

14:02 Clinical and pathophysiologic parallels between CLAD and chronic pulmonary GVHD: Pathophysiological analysis (12 min)
Gregory Berra (Geneva, Switzerland)

14:14 *Discussion - Q&A (6 min)*

14:20 015 - Bile acid aspiration induces fibrosis and deranges surfactant homeostasis in human lungs
Chiara Camillo (Columbia, USA)

14:27 016 - Insights into the lung microenvironment during rejection in lung transplanted patients
Valentina Vaira (Milan, Italy)

14:34 Genetic regulation of allogeneic immunity and lung transplant rejection (18 min + 3 min Q&A)
Scott Palmer (Durham, USA)

14:55 017 - Genome-wide association study of chronic lung allograft dysfunction
Simon Brocard (Nantes, France)

15:02 Telomeres and post-transplant outcomes (18 min + 3 min Q&A)
John McDyer (Pittsburgh, USA)


15:23 018 - Invariant natural killer T cells in lung transplant allografts: a pilot study on surveillance bronchoalveolar lavage cells
Elena Floris (Columbia, USA)

15:30 019 - NK cell-mediated allo-recognition in lung transplantation: A double-edged sword
Xavier Charmetant (Lyon, France)

15:37 020 - The nature of chronic rejection after lung transplantation: A murine orthotopic lung transplant study
Bart Vanaudenaerde (Leuven, Belgium)

15:50 → 16:15

Break



Thursday 12

Scientific Program

16:15 → 18:15

Room Louis Armand

Reviving respiration: innovations in organ preservation and ex vivo lung perfusion

Chairs: **Marcelo Cypel** (Toronto, Canada)
Arne Neyrinck (Leuven, Belgium)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

16:15 Control of anti-donor immunity via ex vivo pre-treatment of the lung allograft with regulatory T cells
Stephen Juvet (Toronto, Canada)

16:30 **021** - Effective and immediate delivery of functional reporter enzymes to the lung using virus-like particles: a first proof-of-concept study in the rat ex-vivo lung perfusion model
Jan Van Slambrouck (Leuven, Belgium)

16:37 Adeno-associated viral vector applied gene therapy to improve lungs for transplantation
Matt Hartwig (Durham, USA)

16:52 Ex-vivo organ engineering : gene therapy applications to ex-vivo lung perfusion
Shaf Keshavjee (Toronto, Canada)

17:07 Mitochondrial therapy during EVLP
Sandra Lindstedt (Lund, Sweden)

17:22 **022** - Lungs from donors with chest trauma can safely be perfused on EVLP - and used for transplantation
Panja Maria Boehm (Vienna, Austria)

17:29 A centralized hub for EVLP and organ distribution: a dream or reality?
Jorge M. Mallea (Jacksonville, USA)

17:44 Cross circulation landscape
Matthieu Glorion (Suresnes, France)



Scan this QR code to consult
and/or upload the Book of Abstracts



16:15 → 18:15

Room Friedrich List

Graft dysfunction: biomarkers

Chairs: Angela Koutsokera
(Lausanne, Switzerland)
Benjamin Renaud-Picard
(Strasbourg, France)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

16:15 Transcriptomics of transbronchial and mucosal biopsies: Updates from the INTERLUNG study
Kieran Halloran (Edmonton, Canada)

16:30 **023** - Banff human organ transplant panel for detecting acute cellular rejection in lung transplant biopsies
Marta Sablik (Paris, France)

16:37 What can small airway brushings add to our diagnostic armamentarium?
John McDyer (Pittsburgh, USA)

16:52 **024** - Multicenter validation of Large Airway Bronchial Wash (LABW) bile acid signature for the diagnosis of aspiration and prediction of chronic lung allograft dysfunction
Chiara Camillo (New York City, USA)

16:59 **025** - Secretory phospholipase A2-IIA in the airways of lung transplant recipients is associated with bile acid aspiration, airway infections and inflammatory mediators: first insight on its role in lung allografts
Elena Floris (Columbia, USA)

17:06 A clinical trial of Torque Teno virus monitoring in lung transplantation - The VIGILUNG study
Jens Gottlieb (Hannover, Germany)

17:21 **026** - Soluble immune check point receptors as possible markers of rejection in lung transplanted patients
Ilaria Righi (Milan, Italy)

17:28 **027** - A blood gene signature to prognose chronic lung allograft dysfunction
Richard Danger (Nantes, France)


17:35 **028** - Dynamic ¹⁹F MRI of pulmonary ventilation in lung transplant recipients with and without chronic lung allograft dysfunction: a feasibility study
Saskia Bos (Newcastle, UK)

17:42 Cell-free donor-derived DNA: where are we at?
Michael Keller (Bethesda, USA)

17:57 **029** - Confirmation of the multi-parametric cfDNA algorithm for early allograft injury events in lung transplantation
Pascal Pedini (Corse, France)

18:04 **030** - Baseline lung allograft dysfunction is associated with differential kinetics for total and donor-derived cell-free DNA after lung transplantation
David Ross (Los Angeles, USA)

20:30 Dinner at RADIOEAT restaurant
Upon reservation



Friday 13

Scientific Program

9:00 → 10:30

Room Louis Armand

PGD precision: navigating perioperative strategies for optimal outcomes

Chairs: Jason Christie (Philadelphia, USA)
Arne Neyrinck (Leuven, Belgium)

Invited speaker: 18 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

09:00 The upgraded PGD toolbox:
Prediction algorithm and best
management strategies
Jason Christie (Philadelphia, USA)

09:21 **031** - Spatially resolved immune
cell infiltration at the vascular-
bronchial interface in primary graft
dysfunction: lessons from a 72h
porcine transplant model
Nicholas Bechet (Lund, Sweden)

09:28 **032** - Proteomic profiling of primary
graft dysfunction in a porcine
model of lung transplantation
Anna Niroomand (Lund, Sweden)

09:35 Role of genetic susceptibility and
natural killer cells in PGD and ARDS
Daniel Calabrese (San Francisco, USA)

09:56 Debate: Operative and post-
transplant ECMO for everyone?
• Pro: Jasleen Kukreja
(San-Francisco, USA) (10 min)
• Con: Konrad Hoezenecker
(Vienna, Austria) (10 min)
• Discussion (10 min)

9:00 → 10:30

Room Friedrich List

Evil humors: antibodies and how to tame them (Post LTx)

Chairs: Jérôme Le Pavec
(Le Plessis Robinson, France)
Debbie Levine (Stanford, USA)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A


09:00 Cellular targets of donor-specific
antibodies and mechanisms of
injury
Elaine Reed (Los Angeles, USA)

09:15 **033** - Anti-HLA antibodies,
donor-specific antibodies and AMR
in restrictive allograft syndrome:
a nested case-control study
Robin Vos (Leuven, Belgium)

09:22 HLA DSA and non HLA DSA:
Please help us sort this out
Adriana Zeevi (Pittsburgh, USA)

09:37 Local production of intragraft
donor-specific antibodies in lung
transplantation
Tereza Martinu (Toronto, Canada)

09:52 **034** - Altered pIgR/IgA mucosal
immunity in bronchiolitis obliterans
syndrome (BOS): a new player in
the triggering of BOS?
Olivier Brugière (Suresnes, France)



09:59 New AMR classification
Debbie Levine (Stanford, USA)

10:14 **035** - CD38 antibody daratumumab as an add-on rescue therapy for AMR - First report in clinical lung transplantation
Caroline Hillebrand (Vienna, Austria)

10:21 **036** - Extracorporeal photopheresis in lung transplantation, real-life indication not limited to BOS
Louis Maurier (Nantes, France)

10:30 → 10:45

Break

10:45 → 12:15

Room Louis Armand

Pre-transplant allosensitization and induction strategies

Chair: Adriana Zeevi (Pittsburgh, USA)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

10:45 Desensitization strategies
Antoine Roux (Suresnes, France)

11:00 **037** - The impact of preformed donor-specific antibodies on outcome after lung transplantation: a retrospective single-center expérience
Sophia Auner (Vienna, Austria)

11:07 Lessons learnt in lung transplant immunological matching and mismatching (18 min + 3 min Q&A)
Greg Snell (Melbourne, Australia)

11:28 **038** - Induction therapy in the light of the novel biomarker: Torque Teno Virus
Zsafia Kovacs (Vienna, Austria)


11:35 **039** - TTV guided belatacept conversion after lung transplantation: a report of 22 cases
Caroline Hillebrand (Vienna, Austria)

11:42 Debate: Induction therapy in lung transplantation

- Pro: Peter Jacksh (Vienna, Austria) (10 min)
- Con: Andrew Fisher (Newcastle, UK) (10 min)
- Discussion (10 min)



Scan this QR code to consult and/or upload the Book of Abstracts



10:45 → 12:15

Room Friedrich List

Clinical aspects of allograft dysfunction: diagnostics to therapeutics

Chairs: Clément Picard (Suresnes, France)
Lianne Singer (Toronto, Canada)

Invited speaker: 12 min + 3 min Q&A

Selected Abstract: 5 min + 2 min Q&A

10:45 040 - The Vienna experience: characterizing acute lung allograft dysfunction in lung transplant recipients
Sophia Auner (Vienna, Austria)

10:52 041 - Systematic assessment of bronchial ischemia and associated prognosis in a ten years cohort of consecutive bilateral lung transplant recipients
Marie Spaes (Suresnes, France)

10:59 Thoracic imaging in lung transplantation: CT, MRI and beyond
Stijn Verleden (Antwerp, Belgium)

11:14 042 - The natural history of pulmonary function before and after development of chronic lung allograft dysfunction in bilateral and single lung transplant recipients
Shahrzad Lari (Los Angeles, USA)

11:21 043 - A quantitative appraisal of airway obliteration and broncho-alveolar collateral ventilation in BOS-explant lungs
Axelle Coppens (Antwerp, Belgium)

11:28 044 - Improvement in quality of life after lung transplantation among patients with and without baseline lung allograft dysfunction
Natalia Belousova (Suresnes, France)

11:35 ScanCLAD study: tacrolimus vs. cyclosporine in lung transplantation
Jesper Magnuson (Gothenburg, Sweden)

11:50 045 - Comparison between standard-release and extended-release formulations of tacrolimus in lung transplantation
Angela Koutsokera (Lausanne, Switzerland)

11:57 Mesenchymal stromal cell therapy for CLAD
Dan Chambers (Brisbane, Australia)

12:15 → 12:45

Break



12:45 → 13:45

Room Louis Armand

Lunch Academic symposium supported by

GRIFOLS & 

CMV

Chairs: Vincent Bunel (Paris, Canada)
Shahid Husain (Toronto, Canada)

Invited speaker: 15 min + 5 min Q&A

12:45 CMV clinical challenges and monitoring in lung transplantation
Laurie Snyder (Durham, USA)

13:10 CMV treatment
Camille Kotton (Boston, USA)

13:35 Q&A

13:45 → 14:00

Break

14:00 → 14:45

Poster exhibit

Poster session

14:45 → 16:45

Room Louis Armand

Next Future

Chairs: Sandra Lindstedt (Lund, Sweden)
Tereza Martinu (Toronto, Canada)
Antoine Roux (Suresnes, France)
Edouard Sage (Suresnes, France)

Invited speaker: 25 min + 5 min Q&A

14:15 How to set up a new program:
Indian experience
Sandeep Attawar (Hyderabad, India)

14:45 Use of artificial intelligence for graft assessment and allocation
Shaf Keshavjee (Toronto, Canada)

15:15 Xenotransplantation
Bruno Reichart (Munich, Germany)


15:45 Chimerism and tolerance: the holy grail of transplantation?
Joren Madsen (Boston, USA)

16:45 → 17:00

Room Louis Armand

Closing discussion

Sandra Lindstedt (Lund, Sweden)
Tereza Martinu (Toronto, Canada)
Antoine Roux (Suresnes, France)
Edouard Sage (Suresnes, France)



- P1** Histological reclassification after trans-bronchial cryobiopsy in lung transplantation: Analysis of 18 consecutive procedures
Claire Bon (Bordeaux, France)
- P2** Temperature dynamics of donor lungs from procurement to reperfusion: static ice versus controlled hypothermic storage
Ismail Cenik (Leuven, Belgium)
- P3** Tacrolimus intoxication in lung transplant recipients
Eirini Chatzidaki (Zurich, Switzerland)
- P4** Recovery of right ventricular function assessed by MRI in lung transplantation for pulmonary hypertension: role of pulmonary hypertension etiologies and impact on post-transplantation outcome
Dora Dreyfuss (Suresnes, France)
- P5** Comparing patient and clinician perspectives on goals of different donor lung allocation policies
Samuel Kennedy (Newcastle, UK)
- P6** Gender in lung transplantation: Does it matter?
Zsafia Kovacs (Vienna, Austria)
- P7** Primary graft dysfunction in lung transplantation: influence of intraoperative circulatory support mode and consequences for the recipient
Brendan Le Picault (Nantes, France)
- P8** Results from the French compassionate program of maribavir use for refractory CMV infection/disease
Sophie Alain (Limoges, France)
- P9** Late non-catheter-related venous thrombotic events in lung transplant recipients
Letizia Corinna Morlacchi (Milan, Italy)
- P10** Use of dupilumab in asthma relapse after lung transplant
Letizia Corinna Morlacchi (Milan, Italy)
- P11** Systematic review & meta-analysis: pre-lung transplantation body composition and post-lung transplantation outcomes
Annelot Muntinga (Rotterdam, The Netherlands)
- P12** Plasmapheresis before lung transplantation is associated with an increase in tissue factor activity
Tiffany Pascreau (Suresnes, France)
- P13** Analytical and clinical validation of the One Lambda™ Devyser Accept cfDNA kit
Pascal Pedini (Corse, France)
- P14** Colorectal cancer after lung transplantation for cystic fibrosis: incidence and results of colonoscopy screening in a single center
Clément Picard (Suresnes, France)
- P15** The ischemia reperfusion injury and the lung metabolism: development of an extra corporeal lung perfusion rat model
Lorenzo Rosso (Milan, Italy)
- P17** Single center experience of lung preservation, reconditioning and assessment with the organ care system
Marion Villard (Strasbourg, France)
- P18** TNFalpha-pneumocytes II under hypoxia-hypothermia conditions: impact on surfactant secretion
Marion Villard (Strasbourg, France)
- P19** Impact of remdesivir treatment on clinical progression and lung function in lung transplant recipients with COVID-19
Damiana Maria Vulturar (Cluj-Napoca, Romania)
- P20** The increasing contribution of organ donation after euthanasia to the lung transplantation donor pool in the Netherlands
Merel Hellemons (Rotterdam, The Netherlands)
- P21** Hepatitis E after lung transplantation: E for Enigma?
Andrea Zajacova (Prague, Czech Republic)

Aknowledgments



Gold sponsors



Silver sponsors



Sponsors



Endorsed by



Société
Francophone de
Transplantation



Leading the way
in transplantation



ISHLT